Rosario Maselli
Overview
Explore the profile of Rosario Maselli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
667
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pelaia C, Vatrella A, Gallelli L, Terracciano R, Navalesi P, Maselli R, et al.
Expert Opin Biol Ther
. 2017 Oct;
17(12):1565-1572.
PMID: 28990423
Dupilumab is a fully human IgG4 monoclonal antibody directed against the α subunit of the interleukin (IL)-4 receptor (IL-4Rα). Since the activation of IL-4Rα is utilized by both IL-4 and...
2.
Gallelli L, Falcone D, Cannataro R, Perri M, Serra R, Pelaia G, et al.
Drug Des Devel Ther
. 2017 Feb;
11:265-272.
PMID: 28176948
Theophylline is a natural compound present in tea. Because of its property to relax smooth muscle it is used in pharmacology for the treatment of airway diseases (ie, chronic obstructive...
3.
Mazzitelli M, Carida G, Scigliano C, Vallone M, Pirro F, Lombardo M, et al.
Ann Ist Super Sanita
. 2016 Dec;
52(4):530-535.
PMID: 27999224
Background: Continuous spreading of HIV infection may be due to lack of knowledge, especially among young people. It is important to monitor level of knowledge and risk behaviours especially in...
4.
Pelaia G, Vatrella A, Busceti M, Gallelli L, Preiano M, Lombardo N, et al.
Ther Clin Risk Manag
. 2016 Jul;
12:1075-82.
PMID: 27445482
Within the context of the heterogeneous phenotypic stratification of asthmatic population, many patients are characterized by moderate-to-severe eosinophilic asthma, not adequately controlled by relatively high dosages of inhaled and even...
5.
Pelaia G, Vatrella A, Busceti M, Fabiano F, Terracciano R, Matera M, et al.
Pulm Pharmacol Ther
. 2016 Jul;
40:15-21.
PMID: 27381656
Inhaled glucocorticoids are the mainstay of asthma treatment. Indeed, such therapeutic agents effectively interfere with many pathogenic circuits underpinning asthma. Among these drugs, during the last decades budesonide has been...
6.
Pelaia G, Vatrella A, Busceti M, Gallelli L, Calabrese C, Terracciano R, et al.
Ther Clin Risk Manag
. 2015 Oct;
11:1563-72.
PMID: 26504398
Bronchodilators are the most important drugs used for the treatment of chronic obstructive pulmonary disease (COPD). In particular, these therapeutic agents are mostly long-acting compounds utilized via inhalation, and include...
7.
Pelaia G, Muzzio C, Vatrella A, Maselli R, Magnoni M, Rizzi A
Expert Opin Pharmacother
. 2015 Jul;
16(13):2009-21.
PMID: 26194120
Introduction: Chronic obstructive pulmonary disease (COPD) is a complex respiratory disorder, whose medical and socioeconomic burden as one of the main causes of morbidity and mortality is increasing worldwide. COPD...
8.
Pelaia G, Vatrella A, Busceti M, Gallelli L, Calabrese C, Terracciano R, et al.
Mediators Inflamm
. 2015 Apr;
2015:879783.
PMID: 25878402
Asthma is a phenotypically heterogeneous chronic disease of the airways, characterized by either predominant eosinophilic or neutrophilic, or even mixed eosinophilic/neutrophilic inflammatory patterns. Eosinophilic inflammation can be associated with the...
9.
Pelaia G, Maselli R, Gallelli L
Multidiscip Respir Med
. 2015 Feb;
9(1):64.
PMID: 25699181
Chronic obstructive pulmonary disease (COPD) is a widespread respiratory disorder, usually characterized by progressive and poorly reversible airflow limitation. Inhaled long-acting bronchodilators, namely LABA (long-acting β2-adrenergic agonists) and LAMA (long-acting...
10.
Pelaia G, Vatrella A, Busceti M, Gallelli L, Terracciano R, Maselli R
Curr Drug Targets
. 2014 Dec;
16(2):171-8.
PMID: 25523898
The humanized monoclonal anti-IgE antibody omalizumab is currently the only biologic drug approved for asthma treatment. Omalizumab inhibits allergic responses by binding to serum immunoglobulins E (IgE), thus preventing their...